Section one: Contracting authority
one.1) Name and addresses
The NHS Commissioning Board (operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
Contact
Philip Grieve
Country
United Kingdom
NUTS code
UK - UNITED KINGDOM
Internet address(es)
Main address
Buyer's address
one.2) Information about joint procurement
The contract is awarded by a central purchasing body
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
NHS National Framework Agreement for the Supply of Recombinant Von Willebrand Factor
Reference number
CM/PHS/20/5624
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
NHS National Framework Agreement for the supply of Recombinant Von Willebrand Factor. The framework will commence on 1 February 2021 for a period of 5 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 43 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £2,400,000
two.2) Description
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - UNITED KINGDOM
Main site or place of performance
ITT lists purchasing points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors working on behalf of the above.
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of Recombinant Von Willebrand Factor. The framework will commence on 1 February 2021 for a period of 5 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 43 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of use / Weighting: 15%
Price - Weighting: 65%
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2020/S 215-528548
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
12 January 2021
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 0
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Shire Pharmaceuticals Ltd
1 Kingdom Street
London
W2 6BD
Country
United Kingdom
NUTS code
- UK - UNITED KINGDOM
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £2,400,000
Total value of the contract/lot: £1
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
The High Court
Strand
London
WC2A 2LL
Country
United Kingdom